David M Hilbert
Overview
Explore the profile of David M Hilbert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1510
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Edwards J, Swers J, Buonato J, Zaritskaya L, Mu C, Gupta A, et al.
Mol Ther
. 2024 Apr;
32(6):1835-1848.
PMID: 38659225
While conventional chimeric antigen-receptor (CAR)-T therapies have shown remarkable clinical activity in some settings, they can induce severe toxicities and are rarely curative. To address these challenges, we developed a...
2.
Buonato J, Edwards J, Zaritskaya L, Witter A, Gupta A, LaFleur D, et al.
Mol Cancer Ther
. 2022 Jun;
21(7):1171-1183.
PMID: 35737298
Chimeric antigen receptor (CAR) T-cell therapies directed against B-cell maturation antigen (BCMA) have shown compelling clinical activity and manageable safety in subjects with relapsed and refractory multiple myeloma (RRMM). Prior...
3.
Qin H, Edwards J, Zaritskaya L, Gupta A, Mu C, Fry T, et al.
Mol Ther
. 2019 May;
27(7):1262-1274.
PMID: 31043341
Chimeric antigen receptor (CAR) T cell therapies have demonstrated impressive initial response rates in hematologic malignancies. However, relapse rates are significant, and robust efficacies in other indications, such as solid...
4.
LaFleur D, Abramyan D, Kanakaraj P, Smith R, Shah R, Wang G, et al.
MAbs
. 2013 Apr;
5(2):208-18.
PMID: 23575268
The recognition that few human diseases are thoroughly addressed by mono-specific, monoclonal antibodies (mAbs) continues to drive the development of antibody therapeutics with additional specificities and enhanced activity. Historically, efforts...
5.
Kanakaraj P, Puffer B, Yao X, Kankanala S, Boyd E, Shah R, et al.
MAbs
. 2012 Aug;
4(5):600-13.
PMID: 22864384
Despite the clinical success of anti-tumor necrosis factor (TNF) therapies in the treatment of inflammatory conditions such as rheumatoid arthritis, Crohn disease and psoriasis, full control of the diseases only...
6.
Stohl W, Hilbert D
Nat Biotechnol
. 2012 Jan;
30(1):69-77.
PMID: 22231104
For the first time in more than 50 years, the US Food and Drug Administration has approved a drug specifically for the treatment of systemic lupus erythematosus (SLE). This drug,...
7.
Woodland R, Fox C, Schmidt M, Hammerman P, Opferman J, Korsmeyer S, et al.
Blood
. 2007 Oct;
111(2):750-60.
PMID: 17942753
We investigated the mechanism by which B lymphocyte stimulator (BLyS)/BAFF, a tumor necrosis factor superfamily ligand, promotes B-cell survival and resistance to atrophy. BLyS stimulation activates 2 independent signaling pathways,...
8.
Cambridge G, Stohl W, Leandro M, Migone T, Hilbert D, Edwards J
Arthritis Rheum
. 2006 Mar;
54(3):723-32.
PMID: 16508933
Objective: To assess the effects of B lymphocyte depletion on serum B lymphocyte stimulator (BLyS; trademark of Human Genome Sciences, Rockville, MD) levels in patients with rheumatoid arthritis (RA), and...
9.
Collins C, Gavin A, Migone T, Hilbert D, Nemazee D, Stohl W
Arthritis Res Ther
. 2005 Dec;
8(1):R6.
PMID: 16356193
Considerable evidence points to a role for B lymphocyte stimulator (BLyS) overproduction in murine and human systemic lupus erythematosus (SLE). Nevertheless, the correlation between circulating levels of BLyS protein and...
10.
Fleming T, Sachdeva M, Delic M, Beltzer J, Wescott C, Devlin M, et al.
J Mol Recognit
. 2004 Sep;
18(1):94-102.
PMID: 15382264
B lymphocyte stimulator (BLyS) is a tumor necrosis factor (TNF) family member and a key regulator of B cell responses. We employed a phage display-based approach to identify peptides that...